These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients.
    Author: Yang SF, Hsieh YS, Lin CL, Hsu NY, Chiou HL, Chou FP, Chu SC.
    Journal: Clin Chim Acta; 2005 Apr; 354(1-2):91-9. PubMed ID: 15748604.
    Abstract:
    BACKGROUND: The involvements of matrix metalloproteinase-9 (MMP-9) and urokinase plasminogen activator (uPA) in the pathogenesis of various types of lung cancers have been established. The aim of the present study was to determine the concentrations of MMP-9 and uPA in the plasma of nonsmall cell lung cancer (NSCLC) patients. METHODS: Gelatin zymography and ELISA were used to measure MMP-9 and uPA concentrations, respectively, in 90 NSCLC patients and 50 control subjects. RESULTS: Compared with that of control subjects, MMP-9 and uPA levels were significantly higher in the plasma of NSCLC patients (P<0.001 and P<0.01, respectively). Further statistical analysis for clinic pathological parameters revealed that MMP-9 and uPA levels were significantly increased in patients with metastasis (P<0.01 and P<0.05, respectively). Furthermore, the MMP-9 level was significantly different between smokers and nonsmokers (P<0.05) while uPA levels varied between histological types (P<0.05). CONCLUSIONS: Plasma MMP-9 and uPA might play an important role in the metastasis of NSCLC by involvement in the processes of invasion and metastasis.
    [Abstract] [Full Text] [Related] [New Search]